A clinical study of TILs expressing membrane-bound cytokines for the treatment of advanced gynecologic tumors

    A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumors

    A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumors

    A Phase I clinical trial of the autologous natural TIL (GC101) for the treatment of advanced malignant solid tumors

        Juncell Therapeutics completes series A Financing round at a level of nearly ¥ 100 million to accelerate new TIL pipeline advancement

        Raising ¥ 150 million in A+ and A++ rounds, Juncell Therapeutics will accelerate the progress of TIL therapy pipelines!

        Juncell Therapeutics is granted implied IND approval by NMPA for its first TIL therapy

        Juncell Therapeutics wins the highest award in the National Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology

        No lymphodepletion or IL-2 injection required, GC101 TIL demonstrates good safety and objective efficacy in Phase I clinical study!